Application of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) for the prevention of neutropenia in triple negative breast cancer patients older than 65 years during adjuvant chemotherapy


Shuxian Qu;Jianing Qiu;Yidan Zhang;Yongming Liu;Zhendong Zheng;Department of Oncology, The General Hospital of the Northern Theater of the Chinese people's Liberation Army;Department of Oncology of traditional Chinese and Western Medicine, Northeast international hospital;


Department of Oncology, The General Hospital of the Northern Theater of the Chinese people's Liberation Army;Department of Oncology of traditional Chinese and Western Medicine, Northeast international hospital;


Objective The aim of this study was to compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rh G-CSF) and recombinant human granulocyte colonystimulating factor(rh G-CSF) for the prevention of neutropenia in elderly breast cancer patients during adjuvant chemotherapy. Methods A total of 45 oncology inpatients with breast cancer, who received adjuvant chemotherapy and were older than 65 years from May 2017 to October 2018 in the General Hospital of the Northern Theater of the Chinese people's Liberation Army, were included. Epirubivin Cyclophoshamide-Docetaxel(EC-T) sequential adjuvant chemotherapy was chosen. Forty-five patients were randomly divided into two groups; 25 patients in the treatment group were treated with PEG-rh G-CSF and 20 patients in the control group were not treated with PEG-rh G-CSF, but only rh G-CSF. The experimental group was treated with the PEG-rh G-CSF at the end of chemotherapy for 24–48 h, with a 6 mg subcutaneous injection once per chemotherapy cycle. In the control group, rh G-CSF was administered after 48 h of chemotherapy, with a 100 μg subcutaneous injection, 1/d, d 1–7. The dosage could be increased step by step with the exacerbation of neutropenia. The primary aims of this study was to discover the incidence of leukopenia, neutropenia, neutrophilic fever, and adverse reactions in the two groups. Results The incidence of neutropenia, neutrophilic fever and adverse reactions decreased in the treatment group compared to the control group, but no significant difference existed between two groups(P > 0.05). Patients in treatment group had a lower, but not statistically significant, incidence of adverse reactions(P > 0.05).Conclusion Applying PEG-rh G-CSF could be effective in preventing neutropenia in elderly patients with postoperative adjuvant chemotherapy to treat breast cancer. It may effectively control the occurrence of neutropenia after chemotherapy and reduce the chance of infection. The incidence of side effects, such as fever and bone pain, was low. The adverse drug reactions were well tolerated by patients, which could ensure the smooth progress of chemotherapy.


elderly;;breast cancer;;neutropenia;;pegylated recombinant human granulocyte colony-stimulating factor


To explore the background and basis of the node document

Springer Journals Database

Total: 7 articles

  • [1] HE Xu-xun,JIAO Ai-ming,XIA Yue-qin,et al(Department of Medical Oncology,Yancheng Tumor Hospital,Yancheng 224003,China), Study on the effectiveness and the dosage of rhG-CSF given in accordance with the level of leukopenia after chemotherapy, Chinese Journal of Clinical Oncology and Rehabilitation,
  • [2] Jiang Beiqi,Li Zhengdong,Zhuang Zhigang (Department of Lacteal Gland,The First Maternal and Infant Health Care Hospital Affiliated to Tongji University of Shanghai City,Shanghai 200040,China), Studies on clinical safety of two docetaxel regimens in treatment of breast cancer, Adverse Drug Reactions Journal,
  • [3] Yuankai SHI;Jianping XU;Changping WU;Yan ZHANG;Junquan YANG;Tao ZHOU;Zheng LIU;Weidong MAO;Yiping ZHANG;Wei WANG;Zhonghe YU;Lin WU;Jianhua CHEN;Juan WANG;Yonghui AN;Jianhui CAI;Ming LIU;Zhendong CHEN;Qingshan LI;Chaoying REN;Zhiyong YANG;Baolan LI;Min ZHAO;Zhefeng LIU;Bin LIU;Department of Medical Oncology,National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College;Department of Oncology,The Third Affiliated Hospital of Soochow University;Department of Oncology,The First Hospital of Shijiazhuang;Department of Radiochemotherapy Oncology,Tangshan People's Hospital;Department of Medical Oncology,Armed Police Corps General Hospital of Guangdong;Department of Radiotherapy,Handan Central Hospital;Department of Oncology,The Affiliated Jiangyin Hospital of Southeast University Medical College;Department of Medical Oncology,Zhejiang Cancer Hospital;Department of Oncology,Jinzhou Central Hospital;Department of Oncology,Beijing Army General Hospital;Department of Thoracic Medicine,Hunan Cancer Hospital,Affiliated to Xiangya Medical School,Central South University;Department of Oncology,Hebei General Hospital;Department of Oncology,The First Hospital of Hebei Medical University;Deparment of Radiotherapy,The Third Hospital of Hebei Medical University;Department of Medical Oncology,The Second Affiliated Hospital of Anhui Medical University;Department of Radiochemotherapy,Affiliated Hospital of Chengde Medical College;General Department,Beijing Chest Hospital,Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute;Department of Oncology,Hebei Chest Hospital;Department of Oncology,Chinese PLA General Hospital;, Multicenter postmarketing clinical study on using pegylated recombinant human granulocyte-colony stimulating factor to prevent chemotherapy-induced neutropenia, Chinese Journal of Clinical Oncology,
  • [4] Jean Klastersky;;Ahmad Awada, Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?, Critical Reviews in Oncology and Hematology,


Similar documents

Documents that have the similar content to the node document

  • [1] High intensity focused ultrasound in combination with chemotherapy by the regime of PFC: a clinical study for advanced gastric carcinoma, Journal of Nanjing Medical University, 2005 (04)
  • [2] Nanoparticles carry chemotherapy drug deeper into solid tumors, Bulletin of the Chinese Academy of Sciences, 2007 (04)
  • [3] Atsushi Sofuni;Takao Itoi;Fumihide Itokawa;Takayoshi Tsuchiya;Toshio Kurihara;Kentaro Ishii;Syujiro Tsuji;Nobuhito Ikeuchi;Fuminori Moriyasu;, Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy, World Journal of Gastroenterology, 2008 (47)
  • [4] Ping Yang;Qi Zhu;Fuqiang Jiang;, Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature, Chinese Journal of Cancer Research, 2013 (03)